Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.4959
Peer-review started: May 30, 2022
First decision: June 18, 2022
Revised: July 16, 2022
Accepted: August 16, 2022
Article in press: August 16, 2022
Published online: September 14, 2022
Core Tip: Management of refractory ulcerative colitis (UC) experiencing primary non-response or loss of response to biologics is a critical issue. We first summarized the efficacy of cytapheresis (CAP) for such patients. Although CAP tended to have lower effects for induction of remission in patients with UC who were refractory to biologics, combination therapies with CAP and biologics induced clinical remission or response in more than 40% of such patients with UC on average. Given the excellent safety profile of CAP, we believe that this combination therapy can be an alternative therapeutic strategy for such refractory UC patients.